Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

马萨诸塞州剑桥市 - 在生物制药板块一项重大举措中，市值1,280亿美元、财务状况稳健的制药巨头Bristol Myers Squibb（纽交所股票代码：BMY）已达成最终协议，将以每股5.00美元的全现金交易收购2seventy bio, Inc.

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

PRINCETON, N.J. - 欧盟委员会已批准制药巨头Bristol Myers ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...